Your session is about to expire
← Back to Search
Talimogene Laherparepvec + Radiation Therapy for Soft Tissue Sarcoma
Phase 2
Waitlist Available
Led By Steven I Robinson
Research Sponsored by National Cancer Institute (NCI)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
ANC >= 1500/uL
Hemoglobin >= 9 g/dL
Must not have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Upup to 5 years
Awards & highlights
No Placebo-Only Group
Study Summary
This trial is studying the side effects of talimogene laherparepvec and radiation therapy in treating patients with newly diagnosed soft tissue sarcoma.
Eligible Conditions
- Soft Tissue Sarcoma
- Pleomorphic Sarcoma
- Leiomyosarcoma
- Liposarcoma
- Fibrosarcoma
Eligibility Criteria
Inclusion Criteria
You will be eligible if you check “Yes” for the criteria belowSelect...
You are expected to live for at least 3 months with the right treatment.
Select...
Your primary tumor must be bigger than 5cm and located in one place.
Select...
You have a type of cancer called sarcoma that can be treated by injecting the medication into the arms, legs, or trunk.
Select...
You are able to perform daily activities with a certain level of independence and have a good overall health status.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Incidence of post-surgical wound complications
Pathologic complete response (CR) rate
Secondary outcome measures
Incidence of toxicities of T-VEC in combination with radiation therapy
Rate of radiologic response
Rate of surgical response
+4 moreOther outcome measures
Change in PD-L1 expression
Change in tumor infiltrating and circulating immune cells
Clinical outcomes within liposarcoma, leiomyosarcoma, and undifferentiated pleomorphic sarcoma
+1 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Treatment (talimogene laherparepvec, radiation therapy)Experimental Treatment5 Interventions
Patients receive talimogene laherparepvec IT or via intralesional injection at weeks 1, 4, 6 and 8. Beginning 1 week after the start of talimogene laherparepvec, patients undergo radiation therapy on Monday-Friday of weeks 2-6. Patients undergo collection of blood and a tumor biopsy on study and undergo MRI throughout the trial.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Radiation Therapy
2017
Completed Phase 3
~7250
Talimogene Laherparepvec
2008
Completed Phase 3
~630
Biopsy
2014
Completed Phase 4
~1180
Biospecimen Collection
2004
Completed Phase 1
~1540
Magnetic Resonance Imaging
2017
Completed Phase 3
~1250
Find a Location
Who is running the clinical trial?
National Cancer Institute (NCI)Lead Sponsor
13,486 Previous Clinical Trials
41,265,897 Total Patients Enrolled
Steven I RobinsonPrincipal InvestigatorMayo Clinic Cancer Center LAO
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Share this study with friends
Copy Link
Messenger